MBX Biosciences Doses First Patient in Phase 2 Avail™ Trial of MBX 2109 for the Treatment of Hypoparathyroidism
CARMEL, Ind., Aug. 12, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today …